Anti-fibrotic peptide shows early promise against interstitial lung diseaseApril 13, 2016
The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.
Fibrotic diseases, which are characterized by excessive scarring due to overproduction by fibroblasts of collagen or extracellular matrix, account for more than 45% of U.S. deaths--more than cancer--and are estimated to cost $10 billion annually. Despite the prevalence of fibrotic diseases, only a handful of anti-fibrotic agents have been approved by the U.S. Food and Drug Administration, and none is available for systemic sclerosis.
In many ways, systemic sclerosis is the quintessential fibrotic disease, since its scarring can damage any part of the body. "Systemic sclerosis is often more than skin deep, affecting the gastrointestinal tract, the lungs, the heart, the kidneys, and the blood vessels, so it is a model for many other more prevalent fibrotic diseases," says Richard M. Silver, M.D., Director of the Division of Rheumatology and Immunology at MUSC and a co-author on the article. "Whereas there may be 300,000 Americans with scleroderma/systemic sclerosis, millions of others suffer from fibrosis of these other organ systems."
M10 is a ten-amino acid peptide formed from the natural cleavage of the receptor tyrosine kinase MET by the caspase 3. MET, also known as hepatocyte growth factor receptor, is thought to protect against injury and fibrosis, but the mechanisms by which it does so have remained unclear.
The MUSC investigators showed that M10 could protect against fibrotic injury in a bleomycin-induced model of ILD and that its anti-fibrotic effects are likely due to its modulation of the transforming growth factor beta 1 (TGF-β1) pathway. TGF-β1 is a cytokine that has been implicated in inflammation and fibrosis.
"We observed that treatment with M10 by intraperitoneal injection markedly improved bleomycin-induced lung fibrosis in mice, suggesting that the M10 peptide may have potential for use in the treatment of scleroderma-associated interstitial lung disease and other forms of pulmonary fibrosis, for example, idiopathic pulmonary fibrosis," says Galina S. Bogatkevich, M.D., Ph.D., senior author on the Translational Research article. Lead authors for the article are Ilia Atanelishvili, M.S., of MUSC and Yuichiro Shirai, M.D., Ph.D., who holds a dual appointment at MUSC and the Nippon Medical School.
When instilled intratracheally, bleomycin induces fibrotic changes in the lungs, including peribronchial and interstitial infiltration of inflammatory cells, thickening of alveolar walls, and the development of numerous fibrotic lesions with excess deposition of extracellular matrix protein. Using this bleomycin-induced model of lung fibrosis, the MUSC investigators evaluated the anti-fibrotic effects of M10, using a scrambled peptide as a control. The scrambled peptide had the same ten amino acids as M10 but arranged in a different order. Fibrosis was quantitated using the Ashcroft scale, which ranges from 0 (normal) to 8 (totally fibrotic).
As expected, mice receiving bleomycin plus a scrambled peptide showed greater than eight times more lung fibrosis than controls receiving saline and scrambled peptide (Ashcroft scores, 5.63±1.72 vs. 0.69± 0.35). However, Ashcroft scores dropped to 1.67±1.01 when mice were administered both bleomycin and M10, suggesting the anti-fibrotic potential of this peptide.
Because M10 was given on the same day as bleomycin, its anti-fibrotic effects are considered preventive. To establish the therapeutic anti-fibrotic efficacy of M10, Bogatkevich and her MUSC colleagues are planning experiments in which M10 will be administered a week after the instillation of bleomycin, when fibrotic damage has already occurred. If these additional experiments suggest therapeutic efficacy, Bogatkevich hopes to find an industry partner to help take M10 forward into clinical trials.
Many researchers speculate that there is a final common pathway to fibrosis in many different organ systems. If an anti-fibrotic agent is demonstrated to be effective in systemic sclerosis, which can affect many different organs, it could potentially hold promise for treating fibrotic disease that is confined to particular organ systems as well.
Bogatkevich and the other MUSC investigators also performed in vitro studies to assess the efficacy of M10 in decreasing abnormal collagen production/deposition and to shed light on the mechanism by which it does so. Skin and lung fibroblasts were obtained from three deceased patients with systemic sclerosis with confirmed lung involvement. As expected, these fibroblasts showed high levels of collagen production. Incubation of these fibroblasts with M10 reduced collagen expression in a dose-dependent manner. M10 likewise reduced collagen production induced in normal cells by administration of TGF-β1 without affecting baseline collagen levels.
These findings suggest that the anti-fibrotic effects of M10 may rely on its suppression of the TGF-β1 pathway. Indeed, protein interaction assays showed that M10 likely achieves such suppression by interacting with the Smad2 protein, thereby preventing it from binding to Smad3, which is necessary for the downstream inflammatory effects of the TGF-β1 pathway.
Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.
Medical University of South Carolina
Related Pulmonary Fibrosis Articles:
A PET imaging probe developed by Massachusetts General Hospital investigators appears able to diagnose and stage pulmonary fibrosis -- an often life-shortening lung disease -- as well as monitor the response to treatment.
Radiation therapy of the lungs often leads to irreversible connective-tissue changes that cause functional impairments in the pulmonary tissue.
Cedars-Sinai investigators have pinpointed a major cause of pulmonary fibrosis, a mysterious and deadly disease that scars the lungs and obstructs breathing.
Researchers have found that fat-free mass index, but not body mass index, was a significant predictor of survival in patients with idiopathic pulmonary fibrosis (IPF), a debilitating form of pneumonia.
Researchers at Helmholtz Zentrum München, a partner in the German Center for Lung Research, have discovered that the number of myeloid-derived suppressor cells (MDSC) is increased in the blood of patients with idiopathic pulmonary fibrosis.
Patients with suspected pulmonary embolism often undergo computed tomography pulmonary angiography to confirm or exclude the diagnosis.
Vanderbilt University Medical Center has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis.
A team of researchers from nine leading academic hospitals and research centers have published a paper in the early online edition of the journal Cancer that describes pulmonary outcomes among childhood cancer survivors.
In this issue of JCI Insight, a team led by Laura Fredenburgh of Brigham and Women's Hospital shows that alterations in pulmonary arterial stiffness occur early during disease and promote vascular remodeling by altering signaling mediated by prostaglandins, a class of hormones that regulate inflammation, smooth muscle contraction, and vasoconstrictoin.
In this issue of JCI Insight, Mark Jones and colleagues at the University of Southampton in Southampton, UK, used a micro-computed tomography method to create three-dimensional images of fibroblastic foci from patients with idiopathic pulmonary fibrosis.
Related Pulmonary Fibrosis Reading:
Breathing Should Never Be Hard Work: One Man's Journey with Idiopathic Pulmonary Fibrosis
by Robert Davidson (Author)
Robert Davidson was diagnosed with Idiopathic Pulmonary Fibrosis in October 2007 after having difficulties with the fitness test necessary to retain senior level soccer referee status. Rather than give in to the disease and die, he decided to fight and live as normal a life as possible, borrowing from Winston Churchill, the mantra "Never surrender". He and his wife, Heather, believe it was this attitude that led to him "winning" a double lung transplant January 30, 2010, just weeks before he would have died from the disease. This book is about his journey with that life threatening disease.... View Details
Journey of the CareGiver: Battling Pulmonary Fibrosis
by MS, Lois Moody RN (Author)
The latest edition of this book (Surviving Caregiving) is available for the same price at: www.amazon.com/Surviving-Caregiving-Challenges-Lois-Moody/dp/1501029878/ref=sr_1_4?ie=UTF8&qid=1410298234&sr=8-4&keywords=surviving+caregiving View Details
Chronicling Idiopathic Pulmonary Fibrosis: A Collection of Personal Stories
by Sara K. Whisenant (Author)
Receiving a diagnosis of Idiopathic Pulmonary (IPF) can be an intimidating experience. And it can be difficult for new patients to ask hard, personal questions in clinic. But these powerful stories, written by IPF patients and for newly-diagnosed IPF patients, are where those hard questions are answered. That makes this book a must-read for newly diagnosed patients, their families and loved ones. In “Chronicling Idiopathic Pulmonary Fibrosis: A Collection of Personal Stories,” you’ll hear the voices of real patients and family members as they talk about what worries them, the... View Details
Guide to Clinical Management of Idiopathic Pulmonary Fibrosis
by Steven D Nathan (Author), A Whitney Brown (Author), Christopher S King (Author)
This clinically focused pocket guide offers a concise yet complete overview of idiopathic pulmonary fibrosis, covering the most recent information on aspects such as pathophysiology, management, treatment, and clinical trials. The text is easily accessible and offers pulmonologists and other health care professionals with an excellent quick reference tool. Full color images and figures enhance and summarize key aspects of the text.
Idiopathic pulmonary fibrosis is a condition that affects the alveoli and leads to serious lung damage, and the idiopathic nature of this disease means that... View Details
Pulmonary Fibrosis: Coping With a Terminal Disease
by Lifestyle Design Solutions
Pulmonary Fibrosis: Coping With a Terminal Disease by Robert Post
What do you do when you learn you have Pulmonary Fibrosis, a terminal disease for which there is presently no cure? The author relates his personal experience and explains how he has learned to cope with the disease, products and methods he uses for maintaining health and combating progression of the disease and explains how you can, too.
A linked resources section gives advice on finding and using support groups and Pulmonary Rehabilitation programs. Products and sources are identified that the author has... View Details
A Simple Guide To Pulmonary Fibrosis, (Lung Scarring) Diagnosis, Treatment And Related Conditions
This book describes Pulmonary Fibrosis, Diagnosis and Treatment and Related Diseases
“Singapore scientists have found that a protein, Interleukin 11, or IL11, causes fibrosis disease, which can lead to life-threatening conditions.
The discovery paves the way for more effective treatment against fibrosis, where the body produces excessive connective tissue in response to an injury, causing tissue scarring.
When this happens in vital organs such as the heart, kidney or lungs, it not only damages the organ, but could result in organ failure, leading to death.
Fibrotic... View Details
The Best Cure for Idiopathic Pulmonary Fibrosis with Natural Remedies
This is the complete and most comprehensive guide on treating and controlling idiopathic pulmonary fibrosis.
The eBook extensively deals with causes, signs and symptoms of for lung fibrosis, survival possibilities of those with pulmonary fibrosis, the complete procedure for lung transplantation, different types of pulmonary fibrosis and the best treatment options for restoring the lungs' functions quickly.
Every aspect of for pulmonary fibrosis has been discussed in pure layman's terms for a better understanding.
I have written the eBook covering all the... View Details
Ultimate Pulmonary Wellness
by Noah Greenspan (Author), Mark W. Mangus (Editor), Norma MT Braun (Editor)
Ultimate Pulmonary Wellness is a resource for all people living with respiratory disease including patients, their families and caretakers; and clinicians. This well-rounded guidebook is the fusion of twenty-five years of clinical practice, education and research by Dr. Noah Greenspan, board-certified clinical specialist in cardiovascular and pulmonary physical therapy; and Program Director of the Pulmonary Wellness & Rehabilitation Center in New York City. It is one of the most comprehensive works of its kind. This brand new first edition draws together a complex variety of threads, clearly... View Details
The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis by James N. Parker (2002-06-14)
by James N. Parker (Author)
Idiopathic Pulmonary Fibrosis, 1e
by Kevin K Brown MD (Author), Jeffrey Swigris (Author)
Designed with the practicing clinician in mind, Idiopathic Pulmonary Fibrosis provides a succinct, easy-to-digest overview of this challenging condition in which the cause of thickening lung tissue is unknown. This concise resource by Drs. Kevin K. Brown and Jeff Swigris provides essential information for the physician who sees pulmonary fibrosis patients, including epidemiology, genetics and biomarkers, pathology, diagnosis, disease monitoring, and therapeutics intended to improve the patient’s lifespan and quality of life.Covers the process of making the diagnosis of... View Details